Tixagevimab/AZD8895 represents a distinct treatment method utilizing two monoclonal proteins. Specifically, these compounds function by selectively connecting to the receptor-binding region of the SARS-CoV-2 agent, https://www.targetmol.com/compound/tixagevimab